Clomiphene Citrate Effectively Increases Testosterone in Obese, Young, Hypogonadal Men.

S. Bendre, P. Murray, S. Basaria
{"title":"Clomiphene Citrate Effectively Increases Testosterone in Obese, Young, Hypogonadal Men.","authors":"S. Bendre, P. Murray, S. Basaria","doi":"10.4172/2161-038X.1000155","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nObesity has been associated with low testosterone (T) in adult males and in pubertal boys. Therapy for hypogonadism with exogenous T may lead to testicular atrophy and later infertility. Only a few studies have demonstrated that the Selective Estrogen Receptor Modulator (SERM) clomiphene citrate (CC), an estrogen receptor antagonist, increases T in obese hypogonadal men while preventing testicular atrophy. No studies to date using CC have been done in younger obese post-pubertal hypogonadal males.\n\n\nOBJECTIVE\nTo determine whether CC therapy is effective in increasing serum T levels in hypogonadal post-pubertal obese males 18-21 years.\n\n\nMATERIALS AND METHODS\nA retrospective chart analysis of records in obese men aged 18-21 years was done. Patients with early morning T level <350 ng/dl were given 25 mg CC on alternate days. Out of 18 patients found to have low T, 11 were analyzed. Baseline serum T, LH, FSH, weight and BMI were compared at baseline and after 3 months of CC treatment.\n\n\nRESULTS\nBaseline T level was 233 ± 66 ng/dl and increased to 581 ± 161 ng/dl (p<0.0001) after 3 months of CC treatment. Baseline LH levels increased from 3.3 ± 1.6 mIU/mL to 5.7 ± 1.7 mIU/mL (p=0.027). Similarly, baseline FSH levels increased from 2.8 ± 1.5 mIU/mL to 6.2 ± 3 mIU/mL after CC treatment (p=0.026). There was no correlation between baseline or post treatment weight or BMI and the T level, LH, or FSH level.\n\n\nCONCLUSION\nThis is the first study reporting on CC therapy in obese, hypogonadal post-pubertal men 18-21 years. The SERM CC increased T in obese post-pubertal hypogonadal men, similar to efficacy of CC in adult hypogonadal men over the age 21 years. Larger randomized controlled studies to study the safety and potential use of CC to improve T in young obese HG men are needed.","PeriodicalId":21113,"journal":{"name":"Reproductive system & sexual disorders : current research","volume":"14 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2015-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"23","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reproductive system & sexual disorders : current research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2161-038X.1000155","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 23

Abstract

BACKGROUND Obesity has been associated with low testosterone (T) in adult males and in pubertal boys. Therapy for hypogonadism with exogenous T may lead to testicular atrophy and later infertility. Only a few studies have demonstrated that the Selective Estrogen Receptor Modulator (SERM) clomiphene citrate (CC), an estrogen receptor antagonist, increases T in obese hypogonadal men while preventing testicular atrophy. No studies to date using CC have been done in younger obese post-pubertal hypogonadal males. OBJECTIVE To determine whether CC therapy is effective in increasing serum T levels in hypogonadal post-pubertal obese males 18-21 years. MATERIALS AND METHODS A retrospective chart analysis of records in obese men aged 18-21 years was done. Patients with early morning T level <350 ng/dl were given 25 mg CC on alternate days. Out of 18 patients found to have low T, 11 were analyzed. Baseline serum T, LH, FSH, weight and BMI were compared at baseline and after 3 months of CC treatment. RESULTS Baseline T level was 233 ± 66 ng/dl and increased to 581 ± 161 ng/dl (p<0.0001) after 3 months of CC treatment. Baseline LH levels increased from 3.3 ± 1.6 mIU/mL to 5.7 ± 1.7 mIU/mL (p=0.027). Similarly, baseline FSH levels increased from 2.8 ± 1.5 mIU/mL to 6.2 ± 3 mIU/mL after CC treatment (p=0.026). There was no correlation between baseline or post treatment weight or BMI and the T level, LH, or FSH level. CONCLUSION This is the first study reporting on CC therapy in obese, hypogonadal post-pubertal men 18-21 years. The SERM CC increased T in obese post-pubertal hypogonadal men, similar to efficacy of CC in adult hypogonadal men over the age 21 years. Larger randomized controlled studies to study the safety and potential use of CC to improve T in young obese HG men are needed.
克罗米芬柠檬酸盐能有效提高肥胖、年轻、性腺功能低下男性的睾酮水平。
背景:在成年男性和青春期男孩中,肥胖与低睾酮(T)有关。用外源性T治疗性腺功能减退可能导致睾丸萎缩和后来的不育。只有少数研究表明,选择性雌激素受体调节剂(SERM)克罗米芬柠檬酸盐(CC)是一种雌激素受体拮抗剂,可增加肥胖性腺功能低下男性的T,同时防止睾丸萎缩。到目前为止,还没有研究使用CC在青春期后性腺功能低下的年轻肥胖男性中进行。目的探讨CC治疗对提高18-21岁性腺功能低下的青春期后肥胖男性血清T水平是否有效。材料与方法对18 ~ 21岁男性肥胖患者进行回顾性图表分析。清晨T水平< 350ng /dl的患者隔天给予25mg CC。在发现的18例低T患者中,分析了11例。比较CC治疗前后3个月的基线血清T、LH、FSH、体重和BMI。结果基线T水平为233±66 ng/dl, CC治疗3个月后升高至581±161 ng/dl (p<0.0001)。基线LH水平从3.3±1.6 mIU/mL增加到5.7±1.7 mIU/mL (p=0.027)。同样,CC治疗后,基线FSH水平从2.8±1.5 mIU/mL增加到6.2±3 mIU/mL (p=0.026)。基线或治疗后体重或BMI与T水平、LH或FSH水平没有相关性。结论:本研究首次报道了18-21岁青春期后肥胖、性腺功能低下男性的CC治疗。SERM CC在青春期后性腺功能低下的肥胖男性中增加T,与CC在21岁以上性腺功能低下的成年男性中的效果相似。需要更大规模的随机对照研究来研究CC改善年轻肥胖HG男性T的安全性和潜在用途。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信